

ISSN Print: 2664-9926
ISSN Online: 2664-9934
IJBS 2024; 6(1): 73-76
www.biologyjournal.net
Received: 10-01-2024
Accepted: 13-02-2024

Dr. Yazeed T Al- Shammari
Department of Clinical Virology, King Faisal Institute for Viral Research, Riyadh, Saudi Arabia

Dr. Reem A Al- Fayez
Department of Clinical Virology, King Faisal Institute for Viral Research, Riyadh, Saudi Arabia

Corresponding Author:
Dr. Yazeed T Al- Shammari
Department of Clinical Virology, King Faisal Institute for Viral Research, Riyadh, Saudi Arabia

Cytokine storms and immune dysregulation in viral infections

Yazeed T Al- Shammari and Reem A Al- Fayez

DOI: https://www.dx.doi.org/10.33545/26649926.2024.v6.i1a.444

Abstract
Cytokine storms, or hypercytokinemia, represent a hallmark of severe viral infections where the immune system's response becomes dysregulated, leading to pathological consequences. This phenomenon, characterized by an overwhelming release of pro-inflammatory cytokines, plays a critical role in the progression of diseases such as influenza, dengue, Ebola, and more recently, COVID-19. While cytokines are essential for initiating antiviral immunity, their excessive or uncoordinated release contributes to systemic inflammation, vascular dysfunction, tissue damage, and, in many cases, multi-organ failure. This review examines the mechanisms underlying cytokine storms during viral infections, elucidates the signaling pathways involved, highlights viral strategies that hijack immune responses, and discusses current and emerging therapeutic interventions aimed at modulating the hyperinflammatory state. Special emphasis is placed on COVID-19 as a recent case study of global relevance, while drawing comparative insights from other viral infections to underscore the common immunopathological threads.

Keywords: Cytokine storm, immune dysregulation, viral infections, hypercytokinemia, pro-inflammatory cytokines, COVID-19, influenza, dengue, Ebola, immunopathology, therapeutic interventions

Introduction
The human immune system is an intricate and highly regulated network designed to detect, respond to, and eliminate invading pathogens, including viruses. In a well-orchestrated immune response, various cellular and molecular components interact to control infection while minimizing collateral tissue damage. Among these components, cytokines play a central role. Cytokines are low molecular weight glycoproteins that act as signaling molecules, facilitating communication between immune and non-immune cells during immune responses. They orchestrate processes such as immune cell activation, differentiation, migration, and inflammation. Under normal physiological conditions, cytokine levels are tightly regulated. However, during certain infections, this balance is disrupted, leading to a pathological condition referred to as a "cytokine storm" or "cytokine release syndrome" (CRS).

Cytokine storms represent a hyperactive immune state characterized by the excessive and uncontrolled release of pro-inflammatory cytokines, often leading to systemic inflammation, vascular leakage, tissue injury, and multi-organ dysfunction. While initially recognized in the context of graft-versus-host disease and certain immunotherapies, cytokine storms have since been identified as a critical factor in the pathogenesis of several severe viral infections. These include infections caused by highly pathogenic influenza viruses (e.g., H5N1, H1N1), coronaviruses (SARS-CoV, MERS-CoV, and SARS-CoV-2), flaviviruses (e.g., Dengue virus), filoviruses (e.g., Ebola virus), and Hantaviruses. In these diseases, the severity and mortality are not solely determined by the virus itself but are significantly influenced by the host's immune response, particularly the magnitude and duration of the cytokine release.

The term “cytokine storm” has gained substantial attention in recent years, especially during the COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2. In severe cases of COVID-19, patients have shown dramatically elevated levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), interferon-gamma (IFN-γ), and other inflammatory mediators. This overwhelming cytokine production contributes to acute

respiratory distress syndrome (ARDS), thrombosis, and multi-organ failure, which are leading causes of death in hospitalized patients. Autopsy studies of COVID-19 patients have revealed diffuse alveolar damage, extensive immune cell infiltration, and widespread microvascular thrombosis, all consistent with hyperinflammation and immune dysregulation (Del Valle *et al*., 2020) [1]. These observations are not unique to SARS-CoV-2 but rather reflect a recurring immune pathological theme in viral infections that involve cytokine storm syndromes.

The mechanisms that drive cytokine storms are multifactorial and complex. At the onset of infection, the innate immune system responds by recognizing viral components through pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and NOD-like receptors (NLRs). These receptors detect viral RNA or DNA and initiate signaling cascades that activate transcription factors including nuclear factor kappa B (NF-κB) and interferon regulatory factors (IRFs). The result is the production of pro-inflammatory cytokines and type I interferons, which help limit viral replication and activate adaptive immunity. However, in some cases, the immune response fails to self-regulate, and the excessive cytokine production becomes pathogenic. Overactivation of macrophages, dendritic cells, T lymphocytes, and natural killer (NK) cells further amplifies the inflammatory response. Simultaneously, regulatory mechanisms such as the actions of regulatory T cells (Tregs) and anti-inflammatory cytokines like IL-10 may become suppressed, further exacerbating the immune imbalance (Moore and June, 2020) [12].

Viral factors also play a role in modulating the immune response. Some viruses encode proteins that antagonize interferon signaling, delay antigen presentation, or promote immune evasion, thereby prolonging viral persistence and increasing immune activation. For example, Ebola virus glycoproteins activate monocytes and endothelial cells, leading to a cytokine cascade that contributes to shock and vascular collapse. Dengue virus can trigger antibody-dependent enhancement (ADE), a process in which pre-existing antibodies facilitate viral entry into immune cells, increasing viral replication and cytokine release. These viral strategies not only enable immune escape but also fuel the cytokine storm by prolonging and intensifying immune activation (Martina *et al*., 2009) [3].

Clinically, cytokine storms manifest as systemic inflammatory response syndrome (SIRS), often progressing to ARDS, coagulopathy, and multi-organ failure. The laboratory findings typically include elevated levels of IL-6, CRP, ferritin, D-dimer, and lactate dehydrogenase (LDH), along with lymphopenia and elevated liver enzymes. These biomarkers are not only useful for diagnosing the cytokine storm but also serve as prognostic indicators for disease severity and outcomes.



Fig 1: Comparison of Key Biomarkers in Mild vs. Severe COVID-19 Cases

Importantly, early identification of patients at risk for cytokine storm has become a critical component of therapeutic decision-making, particularly in the context of COVID-19 and other acute viral illnesses.

Therapeutically, managing cytokine storms remains a major challenge. Immunomodulatory drugs such as corticosteroids, IL-6 inhibitors (e.g., tocilizumab), IL-1 receptor antagonists (e.g., anakinra), and Janus kinase (JAK) inhibitors (e.g., baricitinib) have been explored for their potential to dampen hyperinflammation. The use of such therapies must be carefully timed to avoid compromising antiviral immunity. Additionally, supportive treatments such as anticoagulation, oxygen therapy, and mechanical ventilation are crucial for managing complications associated with cytokine storms. Personalized medicine approaches, including cytokine profiling and biomarker-based risk stratification, are increasingly being integrated into clinical practice to optimize therapeutic strategies.

Mechanisms Underlying the Cytokine Storm

The onset of a cytokine storm during viral infections begins with the recognition of viral components by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and NOD-like receptors (NLRs). These receptors detect viral RNA or DNA and activate downstream signaling cascades, particularly through nuclear factor-kappa B (NF-κB) and interferon regulatory factors (IRFs), resulting in the transcription of pro-inflammatory cytokines including IL-6, IL-1β, TNF-α, and type I interferons (IFN-α/β) (Liu *et al*., 2016) [4]. While early cytokine release is critical for viral clearance, persistence of viral antigens and inadequate resolution of inflammation amplify this response. Overactivated macrophages and dendritic cells continue to secrete cytokines, while activated T cells contribute to additional interferon-γ (IFN-γ) and TNF-α production.

Concurrently, regulatory mechanisms, particularly involving T regulatory cells (Tregs) and anti-inflammatory cytokines like IL-10, become suppressed or ineffective, allowing unbridled cytokine release to continue (Giamarellos-Bourboulis *et al*., 2020) [5].

Moreover, this storm affects the vascular endothelium, promoting increased permeability, edema, and coagulation abnormalities. The result is tissue hypoxia and systemic inflammation, most notably manifesting in the lungs as ARDS. Multisystem organ involvement reflects the systemic impact of uncontrolled cytokine signaling.

Viral Infections Associated with Cytokine Storms

Historically, severe cases of H5N1 and H1N1 influenza have shown elevated levels of IL-6, TNF-α, and IFN-γ in plasma and bronchoalveolar lavage samples. In particular, patients infected with avian influenza strains exhibit rapid pulmonary infiltration by neutrophils and macrophages, indicating cytokine-driven lung pathology (de Jong *et al*., 2006). Ebola virus disease (EVD) is another classical example, where high circulating levels of IL-6, IL-10, and chemokines such as MCP-1 and IP-10 correlate with fatal outcomes (Wauquier *et al*., 2010) [7]. These cytokines also contribute to vascular leakage and shock, hallmarks of EVD pathology.

Dengue virus presents a slightly different but equally lethal model of immune dysregulation. In severe dengue, cytokines such as IL-10, IL-6, and TNF-α are elevated, and they mediate vascular leakage, leading to dengue hemorrhagic fever or dengue shock syndrome. Interestingly, the phenomenon of antibody-dependent enhancement (ADE) further amplifies cytokine production by facilitating increased viral uptake by Fcγ receptor-bearing immune cells (Martina *et al*., 2009) [3].

COVID-19 has provided a recent and globally scrutinized instance of cytokine storm pathology. In severe SARS-CoV-2 infection, elevated levels of IL-6, IL-1β, and GM-CSF are consistently observed, and these correlate with respiratory failure and poor prognosis (Del Valle *et al*., 2020) [1]. Autopsy studies have confirmed diffuse alveolar damage and immune cell infiltration in lung tissue, consistent with hyperinflammatory responses.

Cytokine Signaling and Immune Dysregulation

The major cytokines implicated in storm syndromes include IL-6, TNF-α, IL-1β, IFN-γ, and IL-10. IL-6, a pleiotropic cytokine, activates downstream pathways via the Janus kinase (JAK) and signal transducer and activator of transcription (STAT3) axis. Overactivation of this pathway leads to persistent systemic inflammation, hematologic abnormalities, and acute phase protein production (Tanaka *et al*., 2014) [8]. TNF-α contributes to endothelial damage and enhances pro-coagulant activity. IL-1β, often activated via the NLRP3 inflammasome, promotes leukocyte recruitment and fever, further amplifying inflammation.

Type I interferons, while critical in early antiviral defense, when sustained, contribute to tissue damage and lymphocyte apoptosis. Dysregulated IFN-γ production has been implicated in macrophage activation syndrome (MAS), often considered an extreme form of cytokine storm (Brisse and Wulffraat, 2019) [9]. These cytokines not only function individually but also synergistically, creating a feedback loop that perpetuates the hyperinflammatory state.

Clinical Manifestations and Laboratory Findings

Clinically, patients undergoing cytokine storm present with high-grade fever, hypotension, hypoxia, and rapid progression to ARDS. Laboratory findings include elevated levels of IL-6, ferritin, C-reactive protein (CRP), and D-dimer.



Fig 1: Comparative serum IL-6 levels in healthy individuals, mild COVID-19 patients, and severe COVID-19 cases. Elevated IL-6 is strongly correlated with disease severity and systemic inflammation.

Lymphopenia is commonly observed, reflecting immune exhaustion and redistribution of lymphocytes to inflamed tissues (Zhou *et al*., 2020) [10]. Coagulation abnormalities including elevated fibrinogen and prolonged prothrombin time indicate progression toward disseminated intravascular coagulation (DIC). Organ involvement, particularly liver and kidney dysfunction, signals poor prognosis and the need for aggressive intervention.

Table 1: Biomarkers in Cytokine Storms Associated with Viral Infections

Biomarker	Function / Relevance	Observed Changes	Clinical Significance
IL-6	Major driver of inflammation and CRP production	Elevated in severe cases	Predictor of respiratory failure and poor outcome
CRP	Acute-phase protein stimulated by IL-6	Increased >100 mg/L in COVID-19	Indicator of systemic inflammation
Ferritin	Iron storage; marker of macrophage activation	Elevated (>500 ng/mL)	Associated with hyperinflammation and MAS
D-dimer	Fibrin degradation product; coagulation marker	High levels seen in COVID-19 and H1N1	Associated with thrombosis and DIC
LDH	Marker of tissue injury	Elevated in multi-organ involvement	Reflects lung and liver damage
IL-10	Anti-inflammatory cytokine	Sometimes paradoxically elevated	Reflects dysregulated attempt at suppression
Lymphocyte Count	Reflects immune cell depletion	Decreased (lymphopenia)	Correlates with severity and mortality

Data compiled from Del Valle *et al*. (2020) [1], Wauquier *et al*. (2010) [7], Giamarellos-Bourboulis *et al*. (2020) [5], Tanaka *et al*. (2014) [8], and Zhou *et al*. (2020) [10].

Therapeutic Strategies

Managing cytokine storms involves both antiviral control and modulation of immune responses. Corticosteroids have historically shown mixed outcomes but gained widespread use in COVID-19, with dexamethasone demonstrating mortality benefits in patients requiring oxygen or mechanical ventilation (RECOVERY Collaborative Group, 2020). IL-6 blockade with monoclonal antibodies such as tocilizumab and sarilumab has yielded positive outcomes in subsets of COVID-19 patients, although efficacy depends on timing and disease stage.

IL-1 receptor antagonists like anakinra have also been trialed with moderate success. Janus kinase (JAK) inhibitors such as baricitinib and ruxolitinib target downstream cytokine signaling pathways and are under investigation in several viral infections for their anti-inflammatory potential. Antiviral agents, although not directly affecting cytokines, help reduce viral load and indirectly modulate the immune response.

Supportive therapies, including anticoagulation, fluid management, and oxygen supplementation, remain vital. Convalescent plasma and monoclonal antibody therapies may reduce viral burden, thereby preventing the escalation of immune activation.

Conclusion

Cytokine storms are a critical component of immune dysregulation in severe viral infections, transforming host defense mechanisms into agents of pathology. The interplay of pro-inflammatory cytokines, disrupted regulatory mechanisms, and viral persistence creates a complex immunopathological state requiring timely intervention. Understanding the molecular and cellular drivers of this phenomenon has led to the development of targeted therapies, many of which have shown promise during the COVID-19 pandemic. However, early recognition, stratification of patient risk based on biomarker profiling, and combination therapies hold the key to future management strategies. As the threat of emerging and re-emerging viral infections persists, dissecting the mechanisms of cytokine storm will remain central to improving outcomes in infectious diseases.

References

1. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, *et al*. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-1643. DOI:10.1038/s41591-020-1051-9.
2. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473-474. DOI:10.1126/science.abb8925.
3. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009;22(4):564-581. DOI:10.1128/CMR.00035-09.
4. Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13(1):3-10. DOI:10.1038/cmi.2015.74.
5. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, *et al*. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992-1000.e3. DOI:10.1016/j.chom.2020.04.009.
6. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, *et al*. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12(10):1203-1207. DOI:10.1038/nm1477.
7. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal Zaire *Ebolavirus* infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis. 2010;4(10):e837. DOI:10.1371/journal.pntd.0000837.
8. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. DOI:10.1101/cshperspect.a016295.
9. Brisse E, Wulffraat N, Ängström L, Smets K, Van Loosdregt J, Van Royen-Kerkhof A. Interferon-γ release assay as a diagnostic tool for macrophage activation syndrome. Clin Exp Rheumatol. 2019;37 Suppl 121(6):126-133. PMID:31820369.
10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, *et al*. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. DOI:10.1016/S0140-6736(20)30566-3.
11. Recovery Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, *et al*. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693-704. DOI:10.1056/NEJMoa2021436.